Most Read Articles
Pearl Toh, 3 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 5 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

Rare cases of IBD onset seen in patients with psoriasis on IL-17 inhibitors

10 Aug 2020

The risk of new-onset inflammatory bowel disease (IBD) among patients with psoriasis exposed to interleukin-17 inhibitor (IL-17i) appears to be comparable to that among unexposed individuals, suggests a study. In addition, the incidence of IBD in exposed patients is low.

This retrospective cohort analysis was conducted to compare IBD risk in psoriatic patients with and without IL-17i exposure. Participants were identified using electronic health records data. The primary outcomes were 6-month and 1-year IBD incidence.

Crude 6-month IBD incidence was low at 0.16 percent among patients with psoriasis exposed to any IL-17i, 0.24 percent among those exposed to secukinumab alone, and 0.11 percent among those unexposed. At year 1, IBD incidence was 0.27 percent among IL-17i–exposed patients, 0.32 percent among those exposed to secukinumab alone, and 0.19 percent among those unexposed.

Adjusted analysis revealed no significant difference in the likelihood of developing IBD between exposed and unexposed patients with psoriasis at 6 months (odds ratio [OR], 1.42, 95 percent confidence interval [CI], 0.45–4.43) and 1 year (OR, 1.37, 95 percent CI, 0.57–3.33). There was also no significant difference in the odds of IBD development at 6 months and 1 year between secukinumab-exposed and unexposed patients with psoriasis.

These findings were supported by another study, which found rare cases of IBD onset and exacerbation in patients exposed to IL-17i for the treatment of psoriasis and psoriatic arthritis. [Drugs Context 2020;doi:10.7573/dic.2020-2-1]

The current study was limited by the low number of outcome events, according to the investigators.

Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 5 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.